Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

61.81
Delayed Data
As of Jun 29
 +1.82 / +3.03%
Today’s Change
45.45
Today|||52-Week Range
71.60
+4.34%
Year-to-Date
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Jun 29 / Zacks.com - Paid Partner Content
Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?
Jun 27 / MotleyFool.com - Paid Partner Content
Infinity Regains Duvelisib Rights, Announces Restructuring
Jun 29 / Zacks.com - Paid Partner Content
Better Buy: Merck & Co. Inc. vs. AbbVie
Jun 27 / MotleyFool.com - Paid Partner Content
2016s Top 10 Dividend Stocks
Jun 29 / MotleyFool.com - Paid Partner Content
Stock Market News for June 22, 2016
Jun 22 / Zacks.com - Paid Partner Content
8 Beaten-Down Post-Brexit Bargains
Jun 29 / TheStreet.com - Paid Partner Content
7 Pharmaceutical Stocks With Dividends Yielding More Than 3%
Jun 21 / MotleyFool.com - Paid Partner Content
The FDA Unsurprisingly Approves Gilead's New Hepatitis C Drug. Now What?
Jun 28 / MotleyFool.com - Paid Partner Content
Better Buy: AbbVie Inc. vs. Johnson & Johnson
Jun 19 / MotleyFool.com - Paid Partner Content
Think Healthcare M&A Is Dead? Think Again.
Jun 28 / MotleyFool.com - Paid Partner Content
Steel stocks rise on 'very bullish' hopes
Jun 08 / FT.com - Paid Partner Content
Why Is Gilead Sciences (GILD) Stock Gaining Today?
Jun 28 / Zacks.com - Paid Partner Content
M&A back on the table as 'big pharma' targets smaller rivals
Jun 02 / FT.com - Paid Partner Content
Forget Stem Cell Stocks: Here Are 3 Clinical-Stage Biotechs to Buy Instead
Jun 28 / MotleyFool.com - Paid Partner Content
Cancer doctors face next drug challenge
Jun 01 / FT.com - Paid Partner Content